Can I Take Resveratrol with Spironolactone?

What Is Spironolactone and Why Do People Take It with Supplements?

Spironolactone is a potassium-sparing diuretic and aldosterone antagonist approved by the FDA for hypertension, edema, and heart failure, and used extensively off-label for hormonal acne and hirsutism in women [1]. Its anti-androgenic activity makes it attractive for acne that has not responded to topical agents or antibiotics. A 2017 randomized controlled trial published in JAMA Dermatology (N=410) found that 200 mg/day of spironolactone produced a clinically significant reduction in acne lesion count over 24 weeks compared with placebo [2].

Why Patients Add Resveratrol

Resveratrol is a stilbene polyphenol found in grape skins, red wine, and certain berries. Marketing around longevity, cardiovascular protection, and skin health drives many patients already on spironolactone to add a resveratrol supplement. A 2020 systematic review in Nutrients covering 21 human randomized trials noted resveratrol improved markers of oxidative stress and inflammation, though clinical endpoints remained inconsistent [3]. That appeal is understandable. The concern is what happens inside your liver when both compounds are on board at the same time.

Spironolactone's Metabolic Pathway

Spironolactone is absorbed orally, reaches peak plasma concentration in 1 to 2 hours, and is metabolized primarily in the liver to active metabolites including canrenone and 7-alpha-thiomethylspironolactone [4]. CYP3A4 is the principal enzyme responsible for this biotransformation. Any agent that inhibits or induces CYP3A4 can shift spironolactone plasma levels in a clinically meaningful direction.

How Resveratrol Interacts with CYP3A4

Resveratrol inhibits CYP3A4 activity. This is the most concrete pharmacokinetic concern with the combination.

The In-Vitro Evidence

A 2010 study in Drug Metabolism and Disposition demonstrated that resveratrol inhibited CYP3A4 with a Ki of approximately 4.8 µM in human liver microsomes [5]. At concentrations achievable with high-dose supplementation (500 mg, 1 g per dose), plasma resveratrol and its glucuronide conjugates may reach levels sufficient to slow CYP3A4 activity meaningfully. When CYP3A4 is inhibited, drugs metabolized by that pathway, including spironolactone, may accumulate to higher-than-expected plasma concentrations.

What Higher Spironolactone Levels Could Mean Clinically

Elevated spironolactone exposure could intensify its potassium-sparing effect, raising the risk of hyperkalemia, particularly in patients with chronic kidney disease or those co-prescribed ACE inhibitors or ARBs. The FDA label for spironolactone already carries a warning about hyperkalemia, noting serum potassium must be monitored in at-risk patients [6]. Dizziness, menstrual irregularity, and breast tenderness are also dose-dependent side effects that might increase if plasma levels climb.

Dose Matters

Standard OTC resveratrol capsules (100 to 250 mg) probably do not produce plasma concentrations high enough to cause dramatic CYP3A4 inhibition in most people. The Ki data from in-vitro studies frequently exceed concentrations seen with typical oral dosing, because resveratrol has low oral bioavailability of roughly 1% before first-pass metabolism [7]. High-dose formulations (500 mg, 5 g/day) and novel delivery systems designed to improve bioavailability represent a different and less characterized risk profile.

Resveratrol as a Phytoestrogen: The Pharmacodynamic Overlap

Beyond enzyme inhibition, resveratrol binds estrogen receptors alpha and beta with selective estrogen receptor modulator (SERM)-like activity. This is a pharmacodynamic interaction with spironolactone's own hormonal profile.

Resveratrol's Estrogenic Mechanism

A 2002 study in Endocrinology showed that resveratrol activated estrogen-responsive genes in MCF-7 breast cancer cells, binding ERalpha with roughly 7,000-fold lower affinity than 17-beta-estradiol but producing measurable transcriptional activity [8]. In practical terms, resveratrol behaves as a weak estrogen agonist at some tissues and a weak antagonist at others, similar to the SERM tamoxifen.

Spironolactone's Hormonal Effects

Spironolactone itself has anti-androgenic and mild progestogenic properties. At doses of 100 to 200 mg/day used for acne, it lowers free testosterone and may alter the estrogen-to-androgen ratio [9]. Adding a weak estrogenic supplement on top of that hormonal shift could theoretically amplify estrogen-related side effects such as breast tenderness, irregular bleeding, or mood changes. The magnitude of this effect in the clinical setting has not been formally studied in a dedicated human trial, which is an important gap in the literature.

Who Carries Higher Risk from This Overlap

Patients with a personal or family history of estrogen-sensitive conditions, including ER-positive breast cancer, uterine fibroids, or endometriosis, should be especially cautious about adding any phytoestrogen to a regimen that already modulates sex hormones. The Endocrine Society's 2023 guidelines on phytoestrogens note that evidence for clinical harm is limited but that individualized risk assessment is warranted for patients on concurrent hormone-active medications [10].

Potassium: The Third Variable

Spironolactone blocks aldosterone receptors in the distal nephron, reducing urinary potassium excretion and raising serum potassium. Resveratrol itself has no established direct effect on potassium handling. However, the CYP3A4 inhibition pathway described above could indirectly raise serum potassium by pushing spironolactone levels higher.

When to Check Labs

The FDA label for Aldactone (spironolactone) recommends baseline electrolytes and periodic monitoring in patients with impaired renal function or those on concomitant drugs that affect potassium [6]. If you are adding high-dose resveratrol, requesting a basic metabolic panel at the 4 to 6 week mark is a straightforward precaution. A serum potassium above 5.5 mEq/L should prompt contact with your prescriber before continuing.

Factors That Amplify Risk

Patients taking spironolactone alongside ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), or NSAIDs already carry an elevated baseline hyperkalemia risk. Stacking a CYP3A4 inhibitor on top of that combination increases the number of moving parts. Low-dose resveratrol (100 to 250 mg/day from a standard capsule) is likely a minor additional variable, but it is still a variable worth disclosing.

What the Existing Human Data Actually Shows

Most of the interaction evidence between resveratrol and CYP3A4 substrates comes from in-vitro microsomal studies and rodent pharmacokinetic experiments. Dedicated human clinical trials measuring spironolactone plasma levels in the presence of resveratrol have not been published as of mid-2025.

Extrapolating from Comparable CYP3A4 Substrates

A 2008 clinical pharmacokinetic study in British Journal of Clinical Pharmacology tested the effect of resveratrol (1 g daily for 4 weeks) on the AUC of buspirone and verapamil, two established CYP3A4 substrates, and found no statistically significant change in AUC for either drug [11]. That finding suggests moderate-dose resveratrol may not produce clinically relevant CYP3A4 inhibition in vivo, even when in-vitro data predict otherwise, largely because of resveratrol's poor bioavailability. Spironolactone was not studied in that trial, so direct extrapolation has limits.

Resveratrol and Hormonal Acne: Any Direct Evidence?

A 2016 pilot study published in the Journal of Drugs in Dermatology (N=20) found that a topical resveratrol gel reduced inflammatory acne lesions by 53.75% over 60 days, likely through antimicrobial and anti-inflammatory pathways rather than systemic hormonal modulation [12]. Oral resveratrol for acne has not been studied in a randomized controlled trial. Patients sometimes combine it with spironolactone hoping for additive skin benefit, but that additive effect is speculative at this point.

A Practical Decision Framework for Patients Already Taking Both

If you are already taking resveratrol and spironolactone together and have not yet talked to your prescriber, use this sequence:

Step 1. Quantify Your Resveratrol Dose

Check the label. Doses at or below 250 mg/day of standard-bioavailability resveratrol carry a lower theoretical interaction risk than high-dose or liposomal formulations exceeding 500 mg/day.

Step 2. Identify Your Spironolactone Indication and Dose

Patients on 25 to 50 mg/day for acne face different stakes than patients on 100 to 200 mg/day for hirsutism or 25 to 50 mg/day for heart failure. Heart failure patients on spironolactone almost always have concurrent ACE inhibitors or ARBs, which raises the baseline hyperkalemia concern regardless of supplements.

Step 3. Get a Basic Metabolic Panel

Ask your prescriber for serum potassium, creatinine, and eGFR if you have not had labs in the past 3 months. An eGFR below 45 mL/min/1.73m² substantially increases hyperkalemia risk with spironolactone [6].

Step 4. Report Any New Symptoms

Breast tenderness, irregular periods, dizziness on standing, muscle weakness, or palpitations all warrant prompt contact with your prescriber. Muscle weakness and palpitations, in particular, may signal hyperkalemia and should not be managed with a "wait and see" approach.

Step 5. Do Not Self-Adjust Spironolactone

If you decide to stop resveratrol, simply discontinue the supplement. If you suspect your spironolactone dose needs adjustment, contact your prescriber. Self-titrating a potassium-sparing diuretic is not safe.

Timing and Dose Separation: Is It Useful Here?

For some supplement-drug interactions, staggering doses by 2 to 4 hours reduces absorption competition. That strategy applies mainly to drugs that interfere at the gut wall level (such as calcium-binding tetracyclines). CYP3A4 inhibition is a systemic, hepatic phenomenon. Separating resveratrol and spironolactone doses by two hours does not meaningfully reduce the interaction risk because both compounds are already absorbed and acting at the liver simultaneously within a few hours of ingestion. Dose separation is not an effective mitigation strategy here.

Special Populations

Women Using Spironolactone for Acne

Most patients using spironolactone for hormonal acne are women of reproductive age. For this group, the estrogenic pharmacodynamic overlap is the primary concern rather than hyperkalemia, because baseline kidney function is usually normal and daily doses are typically 50 to 150 mg. A clinician review in American Family Physician noted that spironolactone at 100 mg/day reduced acne lesion counts by approximately 50 to 70% in observational studies, with menstrual irregularity as the most common reported side effect [13]. Adding a weak phytoestrogen could worsen menstrual irregularity, even if modestly.

Patients with Heart Failure

For patients on spironolactone 12.5 to 50 mg/day as part of guideline-directed medical therapy for heart failure with reduced ejection fraction, the RALES trial (N=1,663) demonstrated a 30% relative risk reduction in mortality at 24 months with spironolactone versus placebo [14]. In that population, any agent that could raise spironolactone exposure or potassium level carries real safety weight. Resveratrol supplementation in heart failure patients on spironolactone should be discussed with a cardiologist before starting.

Older Adults

Resveratrol's poor bioavailability is partly offset in older adults by slower hepatic clearance. A 2015 pharmacokinetic study in Journals of Gerontology (N=30 adults ages 65 to 80) found that peak plasma resveratrol concentrations were approximately 50% higher after a single 1 g dose compared with historical young-adult data [15]. That elevated exposure increases the plausibility of clinically relevant CYP3A4 inhibition in this age group.

What the Guidelines Say About Supplement Disclosure

The American College of Cardiology and American Heart Association's 2022 guideline on heart failure management explicitly states: "Patients should be counseled to disclose all dietary supplements to their care team, as pharmacokinetic interactions with guideline-directed medical therapy remain incompletely characterized" [16]. The Endocrine Society echoes this for patients on hormone-active medications, recommending that providers systematically ask about supplement use at every visit [10].

Patients often assume supplements are safe simply because they are available without a prescription. That assumption is understandable. It is also incorrect for a non-trivial subset of products, resveratrol among them.

Alternatives Worth Discussing with Your Prescriber

If you are taking resveratrol specifically for skin health, evidence-based alternatives with lower interaction potential include topical niacinamide (4% formulations showed a 47.5% reduction in sebum excretion in a 2017 trial published in Clinical, Cosmetic and Investigational Dermatology) [17] and zinc supplementation at 30 to 45 mg elemental zinc daily, which has demonstrated modest anti-inflammatory effects on acne in a 2020 Cochrane review [18]. Neither compound is a known CYP3A4 inhibitor, and neither carries established estrogenic activity, making them lower-risk options for patients on spironolactone.